APTX - Aptinyx Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.4400
-0.1300 (-3.64%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.5700
Open3.6000
Bid0.0000 x 800
Ask3.8800 x 1200
Day's Range3.3400 - 3.6000
52 Week Range2.8800 - 32.2500
Volume134,735
Avg. Volume257,587
Market Cap115.805M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.1440
Earnings DateAug 12, 2019 - Aug 16, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Trade prices are not sourced from all markets
  • Aptinyx's Shares March Higher, Can It Continue?
    Zacks8 days ago

    Aptinyx's Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Aptinyx.

  • GlobeNewswire12 days ago

    Aptinyx Salutes Retiring Chief Scientific Officer and NMDA Receptor Drug Discovery Pioneer, Joseph Moskal

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Joseph Moskal, Ph.D., the company’s chief scientific officer, will be retiring from his position with the company and focusing on his academic work as a  professor at Northwestern University. Dr. Moskal will continue his close association with Aptinyx in a senior advisory capacity. “Joe has been working in brain research for decades and is a true pioneer in NMDA receptor pharmacology,” said Norbert Riedel, Ph.D., president and chief executive officer of Aptinyx.

  • GlobeNewswire28 days ago

    Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783 on Alcohol-Seeking Behavior and Relapse-Like Behavior in Multiple Models of Alcohol Use Disorder

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the presentation of preclinical data on its novel NMDA receptor modulator, NYX-783, demonstrating that the product candidate robustly attenuated alcohol-seeking and relapse-like behavior in multiple models of alcohol use disorder. “Given the increasingly recognized societal impact of substance abuse, and the lack of safe and effective therapies, we are very encouraged by the activity demonstrated by NYX-783 in these preclinical models of alcohol use disorder,” said Cassia Cearley, Ph.D., vice president of research at Aptinyx.

  • GlobeNewswirelast month

    Aptinyx to Present at the 2019 BMO Prescription for Success Healthcare Conference

    EVANSTON, Ill., June 18, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Ashish Khanna, chief financial officer and chief business officer, will present at the 2019 BMO Prescription for Success Healthcare Conference. Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.

  • GlobeNewswirelast month

    Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive top-line results from a 23-patient, single-blind, sequential design Phase 2 study of its novel NMDA receptor modulator, NYX-2925, in patients with fibromyalgia. Administration of NYX-2925 resulted in statistically significant effects on the primary endpoint, brain activity biomarkers associated with central pain processing, measured using advanced imaging techniques.

  • Could The Aptinyx Inc. (NASDAQ:APTX) Ownership Structure Tell Us Something Useful?
    Simply Wall St.2 months ago

    Could The Aptinyx Inc. (NASDAQ:APTX) Ownership Structure Tell Us Something Useful?

    Every investor in Aptinyx Inc. (NASDAQ:APTX) should be aware of the most powerful shareholder groups. Institutions...

  • GlobeNewswire2 months ago

    Aptinyx Reports First Quarter 2019 Financial Results and Provides Corporate Update

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the first quarter of 2019 and announced recent business highlights. This information will be used for a second Phase 2 study in DPN, which we intend to initiate during the second half of the year alongside a Phase 2 study of NYX-2925 we plan to initiate in fibromyalgia. Additionally, we initiated a Phase 2 study of NYX-783 in post-traumatic stress disorder (PTSD) and expect top-line data to be available in the first half of 2020.

  • Were Hedge Funds Right About Dumping Aptinyx Inc. (APTX) ?
    Insider Monkey2 months ago

    Were Hedge Funds Right About Dumping Aptinyx Inc. (APTX) ?

    We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of December 31st. In this article, we look at what those funds think of Aptinyx Inc. (NASDAQ:APTX) based on that data. […]

  • GlobeNewswire3 months ago

    Aptinyx Appoints Henry Gosebruch to Its Board of Directors

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Henry O. Gosebruch to its board of directors, effective as of May 6, 2019. Since 2015, Mr. Gosebruch has served as executive vice president and chief strategy officer at AbbVie, a global biopharmaceutical company.

  • GlobeNewswire3 months ago

    Aptinyx to Report First Quarter 2019 Financial Results on Tuesday, May 14, 2019

    EVANSTON, Ill., May 06, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, May 14, 2019, at 8:00 A.M. ET to report first quarter 2019 financial results and to discuss recent business updates. Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease.

  • MoneyShow3 months ago

    Biotech Bets and a Goodbye from a Favorite Expert

    After nearly 38 years, small cap, biotech expert Bill Mathews is retiring as editor of The Cheap Investor; we wish Bill and his wife Karen the very best for their coming years. Meanwhile, we leave our readers with some of Bill's parting comments on some of his favorite biotech ideas.

  • GlobeNewswire3 months ago

    Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported positive results from a Phase 1 study of its novel NMDA receptor modulator, NYX-458, in clinical development for the treatment of cognitive impairment associated with Parkinson’s disease. “We are very encouraged by the favorable safety and tolerability profiles we continue to observe with compounds generated from our platform,” said Norbert Riedel, Ph.D., president and chief executive officer of Aptinyx.

  • GlobeNewswire3 months ago

    Robust Analgesic Activity of Aptinyx’s NYX-2925 in Advanced DPN Patients Revealed Through Further Analysis of Data from Phase 2 Study

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today highlighted detailed analysis of the recently completed Phase 2 study of its novel NMDA receptor modulator, NYX-2925, in patients with painful diabetic peripheral neuropathy (DPN). “In patients who experience chronic pain, there can be an evolution in the disorder over time as pain processing shifts from peripheral to central sensitization. This central manifestation of pain becomes more prominent in patients who have had chronic pain for a long time and most therapies offer little relief for these patients.

  • GlobeNewswire4 months ago

    Aptinyx to Present at 18th Annual Needham Healthcare Conference

    EVANSTON, Ill., April 04, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the 18th Annual Needham Healthcare Conference. Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate – rather than block or over-activate – NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.

  • GlobeNewswire4 months ago

    Data in Parkinson’s Disease Model in Non-human Primates Demonstrate Reversal of Cognitive Deficits with Novel NMDA Receptor Modulator, NYX-458

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive preclinical data on its novel NMDA receptor modulator, NYX-458, demonstrating reversal of cognitive deficits in a non-human primate model of Parkinson’s disease. “With up to half of all people with Parkinson’s disease experiencing cognitive impairment and very few therapeutic options addressing these cognitive deficits, the unmet need in Parkinson’s cognitive impairment is immense,” said Norbert Riedel, Ph.D., president and chief executive officer at Aptinyx.

  • GlobeNewswire4 months ago

    Aptinyx to Present Detailed Results from Phase 2 Painful DPN Study of NYX-2925 at American Pain Society Scientific Meeting

    EVANSTON, Ill., March 28, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced an upcoming poster presentation highlighting the detailed results from a recently completed Phase 2 study of NYX-2925 for the treatment of painful diabetic peripheral neuropathy (DPN). The poster presentation will take place at the American Pain Society Scientific Meeting in Milwaukee, Wisconsin on April 4, 2019. “While we announced in January that the study did not meet the primary endpoint in the total study population, the findings from the detailed analysis provide a strong scientific foundation for advancing the development of NYX-2925 for the treatment of chronic pain,” said Norbert Riedel, president and chief executive officer of Aptinyx.

  • All You Need to Know About Aptinyx Inc. (APTX) Rating Upgrade to Buy
    Zacks4 months ago

    All You Need to Know About Aptinyx Inc. (APTX) Rating Upgrade to Buy

    Aptinyx Inc. (APTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • GlobeNewswire4 months ago

    Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimer’s & Parkinson’s Diseases

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming presentations highlighting preclinical data on its novel NMDA receptor modulator, NYX-458, at the AD/PD 14th International Conference on Alzheimer’s & Parkinson’s Diseases in Lisbon, Portugal. “We are excited to present these data, demonstrating the striking effects that NYX-458 has on cognitive impairment in a highly translatable non-human primate model of Parkinson’s disease,” said Cassia Cearley, Ph.D., vice president of research at Aptinyx.

  • GlobeNewswire4 months ago

    Aptinyx Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress

    Completed Phase 2 study of NYX-2925 in painful DPN -- did not meet primary endpoint, but NYX-2925 demonstrated robust analgesic activity in a large and mechanistically relevant.

  • GlobeNewswire4 months ago

    Aptinyx to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 21, 2019

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, March 21st, 2019, at 8:00 A.M. ET to report fourth quarter and full year 2018 financial results and to discuss recent business updates. Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate – rather than block or over-activate – NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.

  • GlobeNewswire5 months ago

    Aptinyx to Present at Cowen and Company 39th Annual Health Care Conference

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the Cowen and Company 39th Annual Health Care Conference. The presentation will take place at 9:20 a.m. ET on March 13, 2019 at The Boston Marriott Copley Place in Boston, MA. Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.

  • GlobeNewswire5 months ago

    Aptinyx to Present at 8th Annual SVB Leerink Global Healthcare Conference

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference. The fireside chat will take place at 9:00 a.m. ET on March 1, 2019 at the Lotte New York Palace in New York City. Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.

  • GlobeNewswire5 months ago

    Aptinyx Initiates Phase 2 Study to Evaluate Safety and Efficacy of NYX-783 in Patients with Post-Traumatic Stress Disorder

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has dosed the first patient in a Phase 2 study of NYX-783 for the treatment of Post-Traumatic Stress Disorder (PTSD). NYX-783 is a novel NMDA receptor modulator and its development in PTSD has been granted Fast Track designation by the U.S. Food and Drug Administration. “PTSD is a devastating condition that affects millions of people for whom the existing therapeutic options offer inadequate symptom relief,” said Norbert Riedel, Ph.D., president and CEO of Aptinyx.

  • Benzinga6 months ago

    The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 16) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioDelivery ...

  • TheStreet.com6 months ago

    Biotech Play Aptinyx Tanks After Drug Trial Fails

    Evanston, IL-based biopharma company Aptinyx Inc. is tanking Wednesday after the phase 2 trial for the company's diabetic peripheral neuropathy treatment did not meet its primary endpoint. The company said that the trial did not demonstrate statistically significant separation in outcomes when compared to a placebo in the double-blind controlled study of 300 patients suffering from the disease.